C-U2WKMitochem Therapeutics
small molecules, mitochondrial dysfunction, cellular metabolism
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-U2WK
C-U2WKC-U2WKsmall molecules, mitochondrial dysfunction, cellular metabolism
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mitsubishi Corporation - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
Ophthalmics Collaboration and Licensing Deals 2019-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert N … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … ation and Licensing Deals 2019-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Eye on the Cure Podcast — Foundation Fighting Blindness Stay up to date on the latest Foundation news and research. Join Today! Close Skip to main content Skip to footer Foundation Fighting Blindness homepage Search My Chapter: Arizona Atlanta Austin Baltimore Charlotte Chicago Cincinnati/Northern Kentucky Cleveland Colorado Columbus Dallas-Fort Worth D.C. Metro Eastern Michigan Fort Wayne Greater New York Hampton Roads/Virginia Beach Houston Indianapolis Jacksonville Kansas City Las Vegas Los Angeles Maine Miami Naples Nashville New England Oklahoma Orange County Oregon Orlando Philadelphia P … Region Washington Wisconsin View Chapter Donate Give Monthly Menu Close Search Submit Understanding Vision Loss Understanding Vision Loss Vision Loss Glossary Retinal Education Videos Achromatopsia Bardet-Biedl Syndrome (BBS) Best Disease Choroideremia CRB1-Associated Diseases Geographic Atrophy (GA) Leber Congenital Amaurosis (LCA) Macular Degeneration PRPH2-Associated Diseases Retinitis Pigmentosa Refsum Disease Stargardt Disease Thyroid Eye Disease Usher Syndrome X-Linked … um VISIONS (United in Vision) Conference Awareness Calendar United In Vision RD Fund Genetic Testing For ECPs About Mission & History Board of Directors Leadership Strategic Council Scientific Advisory Board National Trustees Corporate Partners Financials & Governance Annual Reports Careers Contact Ways to Give Credit Card, ACH & PayPal Tribute Donations Legacy Giving Donor Advised Funds Stock Donations Crypto Donations IRA Charitable Rollover Join a VisionWalk Ho … ion and optimization of overall retinal health. Dr. Rowan will also discuss his grant from the Foundation and the Free Family for studying diet and AMD risk. The grant is also enabling Dr. Rowan to evaluate an FDA-approved drug and an emerging gene therapy as potential AMD preventions. Episode 77: Dr. Bob Bell December 6, 2024. Bob Bell, PhD, chief scientific officer at Ascidian Therapeutics, talks with host Ben Shaberman about STELLAR, the company's Phase 1/2 clinical trial … his journey and ambitions. Peter also reflects on recently receiving a Pulitzer Prize for his team's 15-part series on the role of the AR-15 assault rifle in mass shootings and how the weapon has become one of the best-selling firearms in the US. Episode 65: Matthew Whitaker May 3, 2024. Matthew Whitaker talks to host Ben Shaberman about his rema
%PDF-1.4 %���� 1271 0 obj > endobj xref 1271 26 0000000016 00000 n 0000004727 00000 n 0000004796 00000 n 0000005115 00000 n 0000005362 00000 n 0000005598 00000 n 0000005647 00000 n 0000005686 00000 n 0000005725 00000 n 0000006093 00000 n 0000006788 00000 n 0000007899 00000 n 0000008073 00000 n 0000008321 00000 n 0000008766 00000 n 0000008999 00000 n 0000011707 00000 n 0000023899 00000 n 0000027187 00000 n 0000028132 00000 n 0000034586 00000 n 0000034971 00000 n 0000035024 00000 n 0000072574 00000 n 0000075696 00000 n 0000000816 00000 n trailer ]/Prev 9995646>> startxref 0 %%EOF 1296 0 obj >str … 1265 0 obj > endobj 1266 0 obj > endobj 1267 0 obj > endobj 1268 0 obj >stream application/pdf pettus ISHC2015Program4 2015-08-17T16:09:48Z Word 2018-02-10T13:40:57-05:00 2018-02-10T13:40:57-05:00 Mac OS X 10.10.4 Quartz PDFContext uuid:b1085747-c6cf-df44-af85-a4f0c9a52aa5 uuid:49c939dd-e7dd-b94b-8e05-30843d689d78 endstream endobj 1269 0 obj [()] endobj 1270 0 obj > endobj xref 0 1271 0000000000 65535 f 0000076074 00000 n 0000076784 00000 n 0000078170 00000 n 0000079352 0000
SCbio Spotlights South Carolina’s Leading Life Sciences Industry at BIO International in San Diego LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … and Challenges Brian Hughes 1y Global Biotech Trends in 2022 Lance Kawaguchi 3y Scholarship & Drug Discovery at Novartis Jay Bradner 8y From Academia to Industry: growing in new directions Dirk Gevers 8y Show more Show less Similar topics Future Opportunities in the Life Sciences Sector 5 Posts 124 TechBio Investment Strategies 5 Posts 997 Biotech Innovation Ecosystem 10 Posts 3,158 How Life Sciences Funds Are Expanding 10 Posts 1,905 The Impact of Investments on Life Sci
2026 BIO International Convention | Exhibitor Floor Plan 2026 BIO International Convention Map Your Show DOWNLOAD Selected Exhibitor Search Results Available Booth Zoom In Zoom Out Max Fit Highlight Available Booths Display Booth Dimensions Orientation: Landscape Portrait Print Screenshot Include Booth Results: None Search Results Include Exhibitor Names on Floor Plan: Yes Print Hall(s): Current Hall All Halls Show Available Booths Your floor plan printout is processing. If you selected multiple halls it may take a minute for your print to finish. Loading... Creating Printout..... PRINT MY FLO
BIO 2026: Global Biotech Innovation and Partnerships | SCbio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linke … nds out is how early these students are learning to connect ideas to real-world application. That kind of thinking matters in every field, and especially in biotechnology. Thank you to Florida Invention Convention for creating opportunities that recognize and encourage young innovators. #Amgen #InventionConvention #mycompany #Biotech #STEM 111 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Albany College of Pharmacy and Health Sciences 9,213 fol
TOPRA | Create Account Skip to main content TOPRA Toggle search Keyword search Toggle navigation Keyword search BECOME A MEMBER CONTACT US Sign in About Toggle Our mission, vision and values Our history Governance Who's who Contact us Find us Partnerships and Affiliations What is Regulatory Affairs? Membership & Communities Toggle Join TOPRA TOPRA Membership Communities Volunteering Events Toggle Annual Lecture Awards Regulatory Careers Live Symposium TOPRA Summit Professional Development Toggle Career progression All courses & events Training Conferences & networking … 0, UNITED STATES entreMeDica Inc, Encinitas, 92024, UNITED STATES Entrepreneurs Fund Management, London, SW1Y 6HB, UNITED KINGDOM Envalis, HITCHIN, SG5 1LH, UNITED KINGDOM Envestia, Thame, OX9 3EX, UNITED KINGDOM Envigo, Ely, CB7 4EX, UNITED KINGDOM Enviresearch Ltd, Newcastle upon Tyne, NE1 4DP, UNITED KINGDOM EOC Pharma, Shanghai, 200072, CHINA Eolas Pharma Teoranta, Co. Na Gaillimhe, IRELAND EORTC, BRUSSELS, 1200, BELGIUM EOVET, Sophia Antipolis, 06560, FRANCE EP Pharmaceu … HANA Health Information & Quality Authority, Cork, IRELAND Health Insurance Fund, Skopje, 1000, THE FORMER YUGOSLAV REPUB Health Insurance Fund of the Republic of Srpska, Banja Luka, 78000, BOSNIA AND HERZEGOVINA Health Interactions, Basel, 4051, SWITZERLAND Health Law, mexico, 01050, MEXICO Health Options Europe, London , N113fr , UNITED KINGDOM Health Practice Commission, Grand cayman , KY1-1109, CAYMAN ISLANDS Health Products Regulatory Authority (HPRA) Ireland, Dublin … ham, B43 5 TJ, UNITED KINGDOM Not Applicable (N/A), Jalgaon , 425001, INDIA Not apply, Amersfoort, 3813 BX, NETHERLANDS Not employed, Khartoum , SUDAN NOT FOUND, Istanbul, 34920, TURKEY not found, Mysuru, 570015, INDIA NOT FOUND, NOT FOUND, VIET NAM Not found, Liverpool, M6 5TL, UNITED KINGDOM Not found, Erbil, 44001, IRAQ not found, Bangalore, 560085, INDIA Not found, Muscat, 112, OMAN not found, jeddah, 24245, SAUDI ARABIA Not Found, Paisley, PA2 9QQ, UNITED KINGDOM Not wor
News - SCRA: South Carolina Research Authority Search for: SCRA Membership Menu Get to know SCRA Who We Are Mission Our Boards Board of Trustees Meeting Schedules S&T Meeting Schedule Document Center Our Team Working at SCRA Our Strategic Initiatives What We Do Center for Cybersecurity Center for Research Security Innovation Hubs Our Sustainability Our Impact Get Support SCRA Membership Grant Funding Tech Catalyst Fund Connect to Resources SCRA Member Benefits SCRA’s Startup Resources SCRA Webinars Podcasts Tech Startup Lifecycle Series Thought Leadership Series Solve Industry Needs Get R … Series Thought Leadership Series Solve Industry Needs Get Research Funding SACT Grant Establish South Carolina Location Lease Space Give Support Industry Partnership Fund IPF Newsletter SCRA’s Startup Resources Stay Connected News Media Kit Newsletter Social Freedom of Information Act SC Launch Who We Are Criteria and Eligibility Our Portfolio SCRA Membership SCRA Membership SCRA News Keep up with the latest news from SCRA and news from across the state. Featured Article SCRA … s from SCRA and news from across the state. Featured Article SCRA announces new grant funding, academic funding, and member companies Columbia, S.C. – Volare Boats, Cuffway, SusMaTech, Memberworks, and PSF R&D Labs received new grant funding from the South Carolina Research Authority. Clemson University received new academic grant funding. LivIQ Health, Land Takeoffs, Oral Pouch Solutions, and Petra Loan Servicing were accepted as SCRA member companies. SCRA President and … said, “We welcome these […] Read more News News Releases America’s Seed Fund renewal good news for SC small businesses South Carolina’s small business innovation community received a major piece of good news this spring: Congress has reauthorized the Small Business Innovation Research and Small Business Technology Transfer programs, ending a long period of uncertainty stalling one of the federal government’s most powerful tools for fueling small business growth. For S … y startups focused on improving rural health access. The program, Tech Catalyst Fund, is one of five initiatives within South Carolina’s Rural Health Transformation Program, administered by the Centers for Medicare & Medicaid Services and the South Carolina Department of Health and Human Services. SCDHHS has contracted […] SCRA a
Last Thursday, I had the pleasure of attending an insightful talk by Mohammad Salem, Head of Sales at Immudex. Immudex is a Danish biotech leader at the forefront of developing high-throughput… | Paula Samperio De Torres LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic … board pre-read preparation. This isn’t theory. All of the boards I’m on already apply most of the concepts here (elephant slide, cvp, cover letter, love notes, start with exec session, shorter meetings, etc). Many others do, too. Thanks to the many executives and directors over the years who helped develop the concepts in this article. Much more on how to run effective biotech boards in Gateway (see RA Capital’s website). -Peter Kolchinsky https://lnkd.in/ebuYpad3 RA Capital
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $38,902 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
Create BU Account Skip to main content TOPRA Toggle search Keyword search Toggle navigation Keyword search BECOME A MEMBER CONTACT US Sign in About Toggle Our mission, vision and values Our history Governance Who's who Contact us Find us Partnerships and Affiliations What is Regulatory Affairs? Membership & Communities Toggle Join TOPRA TOPRA Membership Communities Volunteering Events Toggle Annual Lecture Awards Regulatory Careers Live Symposium TOPRA Summit Professional Development Toggle Career progression All courses & events Training Conferences & networking Quali … , France Seno Medical Instruments, Inc., Texas, United States Health Insurance Fund of the Republic of Srpska, , Bosnia and Herzegovina sri ramakrishna paramedical instution, , India not found , Indiana, India Freelancer, , Belgium Progetti S.r.l., , Italy No, , Italy PANPHARMA, , France Bio-Techne Ltd, , United Kingdom Not working, , United States Continuum LLP, , India Pentixapharm AG, , Germany Biocomposites, Staffordshire, United Kingdom GSK, , United Kingdom Accurids Gm … zerland Dompé Albania sh.p.k, , Albania N/A, , Brazil SYFASE, , Greece Not apply, , Netherlands Dompé farmaceutici Spa, , Italy Scottish Health Innovations Ltd, , United Kingdom Biose, , France Biosynetix Ltd, , United Kingdom Bone Therapeutics, , Belgium Boyd Consultants, , United Kingdom BP Pharma Consulting Ltd, Buckinghamshire, United Kingdom Bramart Healthcare Consultancy, Hampshire, United Kingdom , , Nigeria Araclon, Yorkshire, Spain Warburton Technology Limi … tung (BfR), , Germany AstraZeneca UK Limited, , United Kingdom Health Insurance Fund, , The former Yugoslav Repub IFPMA - International Federation of Pharmaceutical Manufacturers & Associations, , Switzerland BIVDA, , United Kingdom TEVA BULGARIA, , Bulgaria Apex pharma, , Egypt 22, Hampshire, United Kingdom Will Pharma, , Belgium , , India Origin Sciences , Cambridgeshire, United Kingdom Scandinavian Regulatory Services, , Sweden National University of Science and Techno … Pharma Österreich GmbH, , Austria Deloitte, , United Kingdom Entrepreneurs Fund Management, , United Kingdom Gedeon Richter UK Ltd, , United Kingdom GlucoRx Ltd, , United Kingdom Jazz Pharmaceuticals Plc, , United Kingdom Mapi SRS, ON, Canada Office for Life Sciences, , United Kingdom Optimity Advisors, , United Kingdom Simon Kucher & Pa
PharmaEssentia Invests $46M in Puerto Rico Bioscience | Invest Puerto Rico posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
%PDF-1.7 %���� 389 0 obj > endobj 521 0 obj >/Filter/FlateDecode/ID[ ]/Index[389 291]/Info 388 0 R/Length 373/Prev 1926630/Root 390 0 R/Size 680/Type/XRef/W[1 3 1]>>stream h���+DQ ��9�41E2���P6^ ���U�Fى���+�$��0��� % ���F)��,��c~����lgy7�>}������T�2J�:��K��� �Iab4O���'���c�NI>0"�W�%�6�g�f���u| _�7�%|n�dpw�~�K�>��� ɩ��Ik���"~��Y{r�)��§q��${�Nd7��7�;8}���~wI��Y�s`J�_�&a�d�5���C��U�&A�Br��_�;�Ka���0 �Z:/x >���/xķ�M��$��=9� ̐���(���$L�����_�=DžE1�u�����?L��?�?����Y�&XƜ�q��?���V��\i�> �Ҵ?�3���?�.Q) endstream endobj startxref 0 %%EOF 679 0 obj >stream h��T]HQ>gf�8���� … `�=s endstream endobj 277 0 obj >stream Acrobat Distiller 8.1.0 (Macintosh) application/pdf art_design NPA_MtgProgram_1.indd 2013-03-01T13:27:34-05:00 Adobe InDesign CS4 (6.0.6) 2013-03-01T10:27:39-05:00 2013-03-01T13:27:34-05:00 uuid:32c3b35c-1ecf-f74b-b552-b9429583e72e uuid:4339aa1a-b78e-44bd-910c-671d4a45c661 endstream endobj 278 0 obj >stream hޔ��N1�_e��v�^�'Ei(i��.��� �"P��� N���t8?/����fJ���m|�B N?���\1�p�X�i O��T]�J��Yѐ�~6Q���N�ʌd��x�P�e�ʲ��g[EV1\cW
Our Portfolio - SCRA: South Carolina Research Authority Search for: SCRA Membership Menu Get to know SCRA Who We Are Mission Our Boards Board of Trustees Meeting Schedules S&T Meeting Schedule Document Center Our Team Working at SCRA Our Strategic Initiatives What We Do Center for Cybersecurity Center for Research Security Innovation Hubs Our Sustainability Our Impact Get Support SCRA Membership Grant Funding Tech Catalyst Fund Connect to Resources SCRA Member Benefits SCRA’s Startup Resources SCRA Webinars Podcasts Tech Startup Lifecycle Series Thought Leadership Series Solve Industry Ne … Series Thought Leadership Series Solve Industry Needs Get Research Funding SACT Grant Establish South Carolina Location Lease Space Give Support Industry Partnership Fund IPF Newsletter SCRA’s Startup Resources Stay Connected News Media Kit Newsletter Social Freedom of Information Act SC Launch Who We Are Criteria and Eligibility Our Portfolio SCRA Membership SCRA Membership SC Launch Inc. Our Portfolio Once SCRA Member Companies receive an investment, they become an SC Launc … from SC Launch Inc. investments contribute to its financial sustainability and fund future investments to continue to achieve its mission of fueling the state’s economy. Some SC Launch Inc. Portfolio Companies take advantage of SCRA-operated facilities and innovation centers throughout the state that offer state-of-the-art lab space and areas for collaborative research. Our SC Facilities program manage the SCRA facilities and innovation centers. Our SC Launch Inc. Portfolio
Foundation Commits $2 Million to Development of a Cross-Cutting Drug Treatment — Foundation Fighting Blindness Stay up to date on the latest Foundation news and research. Join Today! Close Skip to main content Skip to footer Foundation Fighting Blindness homepage Search My Chapter: Arizona Atlanta Austin Baltimore Charlotte Chicago Cincinnati/Northern Kentucky Cleveland Colorado Columbus Dallas-Fort Worth D.C. Metro Eastern Michigan Fort Wayne Greater New York Hampton Roads/Virginia Beach Houston Indianapolis Jacksonville Kansas City Las Vegas Los Angeles Maine Miami Naples Nashville New Engla … Region Washington Wisconsin View Chapter Donate Give Monthly Menu Close Search Submit Understanding Vision Loss Understanding Vision Loss Vision Loss Glossary Retinal Education Videos Achromatopsia Bardet-Biedl Syndrome (BBS) Best Disease Choroideremia CRB1-Associated Diseases Geographic Atrophy (GA) Leber Congenital Amaurosis (LCA) Macular Degeneration PRPH2-Associated Diseases Retinitis Pigmentosa Refsum Disease Stargardt Disease Thyroid Eye Disease Usher Syndrome X-Linked … um VISIONS (United in Vision) Conference Awareness Calendar United In Vision RD Fund Genetic Testing For ECPs About Mission & History Board of Directors Leadership Strategic Council Scientific Advisory Board National Trustees Corporate Partners Financials & Governance Annual Reports Careers Contact Ways to Give Credit Card, ACH & PayPal Tribute Donations Legacy Giving Donor Advised Funds Stock Donations Crypto Donations IRA Charitable Rollover Join a VisionWalk Ho
%PDF-1.6 %���� 5554 0 obj > endobj 5579 0 obj >/Filter/FlateDecode/ID[ ]/Index[5554 49]/Info 5553 0 R/Length 107/Prev 4070669/Root 5555 0 R/Size 5603/Type/XRef/W[1 2 1]>>stream h�bbd``b`��K��{ ��$X �X�@�� V��bi �� {@b_A�/ �� d�+ !z $�"�@�H� �� " a��) L�� #]��o�^��m endstream endobj startxref 0 %%EOF 5602 0 obj >stream h��T�O[U?��Q*eRʗ��J� :VW@X��Rj��a?�#�5%E-��`���Km�_d͖������BL|� ���e��-��MM$~I|�B��ͻ������瞛we?���B. �\H.`�;��-"Ay �� �.���cr�N���&eHU\4�s�p���N@DM�Ne��>ݜ Bq�* ��'$�j|h+�y�\�@��Qx�p�I r�; ���)�+�#3�":�T�j� � |o`�3��+i�H� �i>�,0� … h�U�R�&�-,�4���\��v1�����vU*�ᬗ�+�?�����RS endstream endobj 5570 0 obj >stream application/postscript MUSC_TAG_SOLID_1C Wade Harris Adobe Illustrator CC 2017 (Macintosh) 2016-12-16T10:31:15-05:00 2016-12-16T10:31:15-05:00 2016-12-16T10:31:15-05:00 xmp.did:8a1adcc0-8b30-4a90-a8ea-2a46d8a332e4 xmp.iid:8a1adcc0-8b30-4a90-a8ea-2a46d8a332e4 uuid:4DF1FE1556D511DCB46EF5776AD514E5 proof:pdf uuid:49b68aca-e468-c14b-b4ea-a2a129e378cc xmp.did:b276faca-d625-4a9e-bf4e-f36794ad7e59 uuid:4 … f4e-f36794ad7e59 uuid:4DF1FE1556D511DCB46EF5776AD514E5 proof:pdf converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:5570eab3-a252-4697-88ba-760220f2a23e 2015-08-12T07:42:08-04:00 Adobe Illustrator CC 2015 (Macintosh) / saved xmp.iid:8a1adcc0-8b30-4a90-a8ea-2a46d8a332e4 2016-12-16T10:31:15-05:00 Adobe Illustrator CC 2017 (Macintosh) / Print 1 False False 5.333077 3.739913 Inches Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0 … ���X�A!��m�=-5 T��6�F �g�v���$�¯%����iy75�+"�~%l+�� t��t��]� >stream application/postscript MUSC_TAG_SOLID_1C Wade Harris Adobe Illustrator CC 2017 (Macintosh) 2016-12-16T13:27:10-05:00 2016-12-16T13:27:10-05:00 2016-12-16T13:27:10-05:00 xmp.did:6decd68c-1ece-49d2-a29d-b1e020a8be4b xmp.iid:6decd68c-1ece-49d2-a29d-b1e020a8be4b uuid:4DF1FE1556D511DCB46EF5776AD514E5 proof:pdf xmp.iid:f9569306-1625-4052-9784-eff84662301e xmp.did:f9569306-1625-4052-9784-eff84662301e uui … 784-eff84662301e uuid:4DF1FE1556D511DCB46EF5776AD514E5 proof:pdf converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:5570eab3-a252-4697-88ba-760220f2a23e 2015-08-12T07:42:08-04:00 Adobe Illustrator CC 2015 (Macintosh) / saved xmp.iid:6decd68c-1ece-49d2-a29d-b1e020a8be4b 2016-12-16T13:27:10-05:00 Adobe Illustra
News: SCRA investment in MitoChem 2022Sep06 — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Par … p;became an SCRA Member Company in 2019 and received a $25,000 Academic Startup Grant. It became an SC Launch Inc. Portfolio Company with this investment. MitoChem has also been a long-term tenant at SCRA’s Innovation Center in Charleston. Founded at the Medical University of South Carolina, MitoChem Therapeutics was started by two scientists who saw an opportunity to focus on developing treatments to address the effects of cellular and metabolic dysfunction in neurodegenerat
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Stream episode Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO by Foundation Fighting Blindness podcast | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it Eye on the Cure Podcast | Episode 56: Michael Voevodsky, MBA, CEO by Foundation Fighting Blindness published on 2023-11-06T17:00:00Z Michael Voevodsky, MBA, CEO at MitoChem Therapeutics, talks to host Ben Shaberman about his company's emerging, gene-agnostic treatment designed to boost mitochondrial function for preserving vi
News: press release - 2022Aug15 - ICHOR Life Sciences Invests $1.5 Million — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipe
Photos — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Cellular Meta
%PDF-1.4 %���� 821 0 obj > endobj xref 821 158 0000000016 00000 n 0000005020 00000 n 0000005122 00000 n 0000006174 00000 n 0000006211 00000 n 0000006510 00000 n 0000007254 00000 n 0000007368 00000 n 0000007480 00000 n 0000008116 00000 n 0000008376 00000 n 0000008697 00000 n 0000008836 00000 n 0000009431 00000 n 0000009458 00000 n 0000009717 00000 n 0000011251 00000 n 0000011514 00000 n 0000012115 00000 n 0000012199 00000 n 0000012688 00000 n 0000014260 00000 n 0000014624 00000 n 0000016073 00000 n 0000016658 00000 n 0000016685 00000 n 0000017105 00000 n 0000017365 00000 n 0000017687 00000 n 00 … �1i����s�{�� - c�)�0o5���2 �����e� B�� endstream endobj 975 0 obj >stream application/pdf BR-Header+Canada Adobe Illustrator CS3 2010-04-09T10:48:31-07:00 2010-04-09T10:48:31-07:00 2010-04-09T10:48:31-07:00 256 116 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8 … duY
6lp4kFoMJUkzkerP7Tjf6Vn+cP70lqvtON/pWf5w/vSUjtycffT+lZ9M/nD9x/mkp//Z 72 application/pdf Adobe PDF Library 9.9 False endstream endobj 20 0 obj >/Font >/ProcSet[/PDF/Text]/ExtGState >>>/Type/Page>> endobj 21 0 obj >stream H��Wmo�8��_��A 9���6��_�]�N^�������lVe:�]LhV�Ǹ����$���v��J5�@���^V4�O�m/l!���� r��iV�M[�__9�ۙ:�NO�>q�� h��4�.R�K]��aJڶ�aon&E����- �'���� q��ʪ2�l� ו-uӴYK��+��gJ�W�L�������f�����_~Yޭi��W���H6�ζ��3;��P ���Y뚑s�:���/_v-��]I t�M�ů{U�._)��o����L� … t1n/kk
lK/a3Sv+5mP/ANus/wDJJKV+1ulf9zMf/t1n/kklK/a3Sv8AuZj/APbrP/JJKf/Z 443 application/pdf Adobe PDF Library 9.9 False endstream endobj 41 0 obj > endobj 42 0 obj >]/Height 388/Type/XObject/Decode[0.0 1.0]>>stream ����Adobed���C �� ����� s!1AQa"q�2���B#�R��3b�$r��%C4S���cs�5D'���6Tdt���&� ��EF��V�U(�������eu��������fv��������7GWgw��������8HXhx��������)9IYiy��������*:JZjz����������?���͛6lٳf͛6lٳf … 5j4hZx+SH5vfmP5g/NDRdI
1jW5bvTbn6z69u0cKhvTtJpF3RFbZ0B65VqMMIwJAZwmSX//2Q== application/pdf BR_ad_JUNE_2012 Adobe PDF library 9.00 False 1 True True 8.500000 11.000000 Inches Avenir-Medium Avenir 65 Medium Type 1 001.001 False AveniMed; Avenir Helvetica-Bold Helvetica Bold TrueType 6.0d7e1 False Helvetica.dfont Helvetica Helvetica Regular Tru
Ophthalmics Collaboration and Licensing Deals | Current Partnering The store will not work correctly when cookies are disabled. JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser. My Account My Wish List Sign In Compare Products Create an Account Skip to Content Toggle Nav My Cart Search Search Search Menu Home CP Reports Store Industry sector reports Deal type reports Stage partnered reports Technology reports Therapy reports Subscription services Market forecast reports Current Agreements CP Knowledge Centre CP … price within 7 days of purchase, we will refund the difference. Delivery Deadline We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply) Latest report If an update is published within 30 days of your purchase, you will receive it absolutely free of charge. Serious Security We take your data and security seriously. See our privacy policy … lity, risk, and control are allocated within agreements Designed for real-world application Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including: Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour Advisory, legal, and consult
Login | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer'
Mitochem Therapeutics Inc. Contacts, Email Format & Decision Makers | Seamless.AI Pricing Login Get a Demo Get Started Free Prospecting Made Simple Close modal 1. Contact Info 2. Business Info 3. Calendar Name fields cannot be left blank and cannot use special characters Company Name field cannot be left blank and cannot use special characters Please enter a valid business email. Field cannot be left blank. Phone Number field cannot be left blank or format not recognized Book Your Demo Position at Company VP of Sales Outside Sales Inside Sales Sales Ops Marketing Human Resources C-Suite /
MitoChem Therapeutics - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membe
MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Restoring Cellular Metabolis
Michael Voevodsky - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Michael Voevodsky President & Chief Executive Officer at MitoChem Therapeutics Michael Voevodsky 's Executive Work History Current President & Chief Executive Officer , President & Chief Executive Officer Equilar on 06/17/2026 MitoChem Therapeutics Past To view Michael Voevodsky's complete executive work hi
Team 1 — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Craig C Beeso … lows in his laboratory. Professor Beeson received the MUSC Inventor of the Year award in 2016, and was elected to the rank of National Academy of Inventors fellow by a 2017 selection committee. © Copyright 2025 MitoChem Therapeutics, Inc. Charleston, SC 29401 Contact: [email protected]
3rd Mitochondria-Related Drug Development | Going International Login oder neu anmelden --> Deutsch English Español Italiano --> Sitemap --> Register courses and congresses Educational newsletter Job newsletter Our Partners GI marketing Sitemap Imprint/Contact Navigation Home Course Catalogue --> Education Database Find Jobs Journals Websites --> Scientific articles News About US BLOG 0 Display wish list New search | Conferencedetail 3rd Mitochondria-Related Drug Development Evvnt Promotion / evvnt Archive 12.09.2023 - 14.09.2023 The Bostonian Boston, 26 North Stree
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Ophthalmics Collaboration and Licensing Deals 2019-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscriptions Expert N … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … ation and Licensing Deals 2019-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Drug Delivery Consulting - Pharma - Ophthalmology | Alan L. Weiner,Ph.D.| drugdelconsulting.com DRUGDEL CONSULTING IS INACTIVE. DR WEINER IS RETIRED. Contact Us Ophthalmic and Ocular Consulting: Drug Delivery | Formulations Alan L. Weiner, Ph.D. Home Services Consulting DrugDel/Pharma/Device Technical Writing/ Regulatory Documentation Business Development and Technology Evaluation Project Planning Patent Disclosures Literature Searches Promotional and Marketing Clients/Terms About Publications Drug Delivery Formulation Development Clinical Studies Analytical Preclinical Pharmacology/ Biochemis
Ophthalmics Collaboration and Licensing Agreements Benchmark Report 2026: Structured Analysis of 374 Deals - Upfronts, Milestones, and Royalty Structures Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … t these companies to Excel by clicking here. View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgr … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Create a Free Account to Follow Companies To continue, pleas
Directory | Tech Launch Arizona Skip to main content Search search search Search menu Menu home Home close Close Search search Main Menu About chevron_right Inventions chevron_right Startups chevron_right Incubation chevron_right News & Events chevron_right Contact Us Utility Links Faculty & Staff Entrepreneurs & Enthusiasts Industry Students CTA Menu Submit an Invention Startup Opportunities Available Technologies Main navigation About About TLA Activity & Impact Staff Directory Commercialization Network Wildcat Investor Network Faculty Innovation Ambassadors Advisory Board Jo … Team Resources Submenu for Resources NSF I-Corps Hub Wildcat Philanthropic Seed Fund Wildcat Investor Network "Fueled By Arizona" Logo Program Commercialization FAQ Incubation Incubation for Startups Incubation Team Resources Submenu for Resources NSF I-Corps Hub Wildcat Philanthropic Seed Fund Wildcat Investor Network Commercialization FAQ News & Events News Events Annual Reports Awards & Honors Fast Forward Newsletter Social Media Contact Us Home Directory
%PDF-1.6 %���� 8056 0 obj > endobj 8082 0 obj >/Filter/FlateDecode/ID[ ]/Index[8056 53]/Info 8055 0 R/Length 118/Prev 19625921/Root 8057 0 R/Size 8109/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"��H�D�f3w�I��Fɕ "����h��� ���̀$c�t ��{��;�e�� R$� � bsF��@r�&Fyv�P� "�3 >stream h�b```�� � ��@ (�����������)��Fa-� �ӊ t���㳿M{�ؔ�K$'�0��Pr��w9��`�� j܊ 2@IY��, b �% � �L, L[�&p� � g����r�!���?�g 䟜�9� �S�E�2��a�������L�;���H}`J`��r`�gp�`]�z�}�j���� �����A.��Q�H���+@�5B�� endstream endobj 8057 0 obj >/Metadata 694 0 R/Pages 8036 0 R/StructTreeRoot 802 0 R/Ty … �^�EE���r�/z�mx��+�����5 �q�0���`'t endstream endobj 8070 0 obj >stream application/pdf reversed patent background 2021-06-24T09:04:07-04:00 2021-06-24T09:04:07-04:00 2021-06-24T09:04:05-04:00 Adobe Illustrator 25.2 (Macintosh) uuid:b19bf8b4-95d0-1b48-9c98-f736f08ed8ac xmp.did:dba19c90-5111-40a3-9b76-e6739ea15540 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:454002172D2168118083B3C0240D7038 xmp.did:454002172D2168118083B3C0240D7038 uuid:5D20892493BFDB11914A85 … B3C0240D7038 2019-07-26T16:40:05+02:00 Adobe Illustrator CS5.1 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:dba19c90-5111-40a3-9b76-e6739ea15540 2021-06-24T09:04:03-04:00 Adobe Illustrator 25.2 (Macintosh) / Print Document AIRobin False False 1 24.999956 24.999956 Centimeters Cyan Magenta Yellow Black Default Swatch Group 0 Weiß RGB PROCESS 255 255 255 Schwarz RGB PROCESS 0 0 0 CMYK Rot RGB PROCESS 255 0 0 CMYK Gelb RGB PROCESS 25 … �P6�m�Am�zP ��64? �%�TI�w���N&~ ��% ��Տ�5��9�> ���R,AnƠf��9_��� �A�"n��v{rFp���Z��z5�Ԗ㼤] Z,_�V\ۑ=�� ���y%C�18[�|$����G{}�a4Y����b�{%��Jk3�}˶�/���raJ?IĄ��7�� `��M� ̼��yhh���:Ӂ�9sO.,��4�V�y�i��F�hH >ľ|Yr�&Ƥ��b�Q���3��FP�ʜ �ҹ�C��yS�R^I)��x� =����rX�V����l��B��d���Re���(G��: ��6�lErq!���i��ᅔp�=ۣ�{���{ "%4[*2��g�" �=�Q�v�|�N� ��� )� �s�w�Q@��r��Dy y�\@�t�剑�IO5k�} �w��Ѕ8���-R�D߬��i�M.�i� ����!H�[�GC@ ��]O��K �BzY����������']� f5 X?k@W���� �8� … �����'�'�j��N5��.��҆Q��>���������׆�� N�x endstream endobj 8072 0 obj >stream application/pdf reversed patent background 2021-06-24T09:04:07-04:00 2021-06-24T09:04:07-04:00 2021-06-24T09:04:05-04:00 Adobe Illustrator 25.2 (Macintosh) uuid:b19bf8b4-95d0-1b48-9c98-f736f08ed8ac xmp.did:dba19c90-5111-40a3-9b76-e6739ea15540 uuid:5D20892493BFDB11914A
Photos — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Pipeline &
%PDF-1.6 %���� 3792 0 obj > endobj 3811 0 obj ]/Info 3791 0 R/Filter/FlateDecode/W[1 3 1]/Index[3792 48]/DecodeParms >/Size 3840/Prev 14842091/Type/XRef>>stream x�bbd```b``�"w�H�� ���d���e`v��fo��`�������IƧ[�fj���Al��@�_�R&F�x�P~����>0��h endstream endobj 3839 0 obj >stream x��{PTU ���by�.�vqQP�Uy��x������Pj>`�DP��=(�M�vF���G&mr���?����rz��P���@�5�3��>������s~���}���ν3{�OA�� ~"�5(@�F ��4ȟ�$�Q�g�X"hX��S�Ò ��9��q*�gU����� �5�MЩC�JE��YX�OH4N6�6��s���N���>s"�W{X[��ס��p���F��+���6E��ɦi/�u�T�� ��. �;���ɝ�&�hs>� �KH3�;���=�����Kc[�G� �u��g�s2�c … 2011-11-17T15:56:12-05:00 2011-11-21T16:24:35-05:00 PScript5.dll Version 5.2.2 application/pdf Microsoft Word - Cover jbell uuid:4029ed59-df16-459e-a08a-2d5942b76329 uuid:c3b4479d-5610-4eff-9f14-620acb6a8a90 Acrobat Distiller 8.1.0 (Windows) endstream endobj 2016 0 obj >stream 2011-11-21T16:37:34-05:00 2011-11-17T11:36:27-05:00 2011-11-21T16:37:34-05:00 Adobe Acrobat 8.1 Combine Files application/pdf abjorn uuid:91f2b4b4-1f8b-47ff-8847-75e315258d0f uuid:be940a19-70f3-4795-bd … :00 2011-11-29T02:09:46-05:00 2011-11-29T14:54:25-05:00 Adobe Acrobat Pro 9.2.0 application/pdf abjorn uuid:e78f9828-ff28-4763-a71f-0f967ef7e41a uuid:30d89844-5d51-480b-833a-47acca10aa61 Adobe Acrobat Pro 9.2.0 endstream endobj 2026 0 obj >stream xڜ��j]1 DE�,K�d�t�Mݕ. ���4��___̓�#^�p I��[�B�^�����T�� $6AIu��ɄF�Npr���L���(�c�P.>�s�$�u�0HG�rL6�Oj������ �6�ǜ��Nww�?���C�/���z� |� �9�sl� �9�s���q����! endstream endobj 2027 0 obj >stream x�26�4T0P���w.JM,���
News: press release - 2021Apr14 FDA ODD — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partner … pment incentives, including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval. About MitoChem Therapeutic MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was co-founded by the late Craig Beeson, PhD, and Bärbel Rohrer, PhD, to develop a new approach to treating neurodegeneration and aging diseases b
Mitochem Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 20 Feb 2026 Mitochem Therapeutics, Inc. Holding Company | 2011 | South Carolina, United States | < 10 | www.mitocheminc.com Holding Company | 2011 | South Carolina, United States | < 10 | www.mitocheminc.com Last update 20 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Eye Diseases Congenital Disorders Other Diseases Small molecule drug Disease domain score A glimps … pment incentives, including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval. About MitoChem Therapeutic MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was co-founded by the late Craig Beeson, PhD, and Bärbel Rohrer, PhD, to develop a new approach to treating neurodegeneration and aging diseases by focusing on prot … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Tasmanian tiger back from extinction, Fervo Energy raises $138M, Unicorn Hunters, Happy Ring lands $60M, NFL to NFT, Swipe right on your next founder – DIG SOUTH --> Skip to content dig-south-tech-hub-logo Tech Summit Join / Login Search August 31, 2022 // 8 minutes Tasmanian tiger back from extinction, Fervo Energy raises $138M, Unicorn Hunters, Happy Ring lands $60M, NFL to NFT, Swipe right on your next founder Asheville , Atlanta , Austin , Birmingham , Business Growth , Charleston , Charlotte , Dallas , Emerging Tech , Houston , Jacksonville , Raleigh – Durham , Tampa Bay DIG T … rs from Charleston. Good Growth Capital recently announced a $102 million fund to invest in Boston and North Carolina based companies in the science/tech sectors. Stanfield Gray is founder of DIG SOUTH Tech Media and named by Time Magazine as “One of the 31 people Changing the South”. Venture Asheville announces their Corporate Entrepreneurship Series. This series brings executives from the largest corporations in the world to Asheville for intimate conversati … uthority member companies. Heron Farms and FaithStreet Inc. also received grant funding, according to an SCRA news release. Charleston-based Heron Farms Inc., which operates the world’s first indoor saltwater vertical farm. FaithStreet Inc., is a congregation engagement platform for faith communities and nonprofits. ???? Hey DIG NATION – Did we miss your event, accolade or announcement? Email [email protected] and we’ll share! TECH IN THE SOUTH T
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Mike Voevodsky | Tech Launch Arizona Skip to main content Search search search Search menu Menu home Home close Close Search search Main Menu About chevron_right Inventions chevron_right Startups chevron_right Incubation chevron_right News & Events chevron_right Contact Us Utility Links Faculty & Staff Entrepreneurs & Enthusiasts Industry Students CTA Menu Submit an Invention Startup Opportunities Available Technologies Main navigation About About TLA Activity & Impact Staff Directory Commercialization Network Wildcat Investor Network Faculty Innovation Ambassadors Advisory Boa … Team Resources Submenu for Resources NSF I-Corps Hub Wildcat Philanthropic Seed Fund Wildcat Investor Network "Fueled By Arizona" Logo Program Commercialization FAQ Incubation Incubation for Startups Incubation Team Resources Submenu for Resources NSF I-Corps Hub Wildcat Philanthropic Seed Fund Wildcat Investor Network Commercialization FAQ News & Events News Events Annual Reports Awards & Honors Fast Forward Newsletter Social Media Contact Us Home Person Mi
Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics for Ocular Aging Disease Research - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics for Ocular Aging Disease Research August 15, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Ichor Life Sciences, a preclinical contract research organization, announced a $1.5 million investment in MitoChem Therapeutics. LAFAYETTE, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MitoChem Therapeutics Granted FDA Orphan Drug Designation for Treatment of Retinitis Pigmentosa - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA MitoChem Therapeutics Granted FDA Orphan Drug Designation for Treatment of Retinitis Pigmentosa April 14, 2021 | 2 min read Twitter LinkedIn Facebook Email Print MitoChem Therapeutics, Inc. , a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced … pment incentives, including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval. About MitoChem Therapeutic MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was co-founded by the late Craig Beeson, PhD, and Bärbel Rohrer, PhD, to develop a new approach to treating neurodegeneration and aging diseases by focusing on prot … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Foundation Fighting Blindness Commits $2 Million to MitoChem Therapeutics for Developing a Vision-Saving Drug Treatment that Protects Mitochondrial Function - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developm … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Foundation Fighting Blindness Commits $2 Million to MitoChem Therapeutics for Developing a Vision-Saving Drug Treatment that Protects Mitochondrial Function April 2, 2012 | 2 min read Twitter LinkedIn Facebook Email Print Columbia, MD (April 2, 2012) – The Foundation Fighting Blindness, a nat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Accelerating Treatments for IRDs: 2020 March Progress Report — Foundation Fighting Blindness Stay up to date on the latest Foundation news and research. Join Today! Close Skip to main content Skip to footer Foundation Fighting Blindness homepage Search My Chapter: Arizona Atlanta Austin Baltimore Charlotte Chicago Cincinnati/Northern Kentucky Cleveland Colorado Columbus Dallas-Fort Worth D.C. Metro Eastern Michigan Fort Wayne Greater New York Hampton Roads/Virginia Beach Houston Indianapolis Jacksonville Kansas City Las Vegas Los Angeles Maine Miami Naples Nashville New England Oklahoma Orange … Region Washington Wisconsin View Chapter Donate Give Monthly Menu Close Search Submit Understanding Vision Loss Understanding Vision Loss Vision Loss Glossary Retinal Education Videos Achromatopsia Bardet-Biedl Syndrome (BBS) Best Disease Choroideremia CRB1-Associated Diseases Geographic Atrophy (GA) Leber Congenital Amaurosis (LCA) Macular Degeneration PRPH2-Associated Diseases Retinitis Pigmentosa Refsum Disease Stargardt Disease Thyroid Eye Disease Usher Syndrome X-Linked … um VISIONS (United in Vision) Conference Awareness Calendar United In Vision RD Fund Genetic Testing For ECPs About Mission & History Board of Directors Leadership Strategic Council Scientific Advisory Board National Trustees Corporate Partners Financials & Governance Annual Reports Careers Contact Ways to Give Credit Card, ACH & PayPal Tribute Donations Legacy Giving Donor Advised Funds Stock Donations Crypto Donations IRA Charitable Rollover Join a VisionWalk Ho … is our pro bono counsel supporting the Foundation Fighting Blindness and our RD Fund. You are a great partner to work with on our journey. So, jumping into it, it's always good to start with the mission. I know this is familiar to everyone. The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, age-related macular degeneration, Usher Syndrome and the enti … on top of it, we're looking forward to helping you. We are discussing possible grant extensions, milestone extensions if needed. And we were even considering, some grant application deadline extensions but, looks like so far, it's not needed. So, it is good to know that everyone, is staying on track with the upcoming grant application deadlines.
MitoChem Therapeutics | The Org Platform Enrich Pricing Log in Sign up MitoChem Therapeutics 0 followers With funding from Foundation Fighting Blindness and the NIH the company synthesized compounds that demonstrate promise for treating vision loss from retinitis pigmentosa, age-related macular degeneration and glaucoma. Industries Biotechnology Headquarters Charleston, United States Employees 11-50 Links Org chart Teams Offices Positions ( 4 ) Unverified Org chart Michael Voevodsky President & CEO 1 Michael Voevodsky Collapse Bärbel Rohrer Co-Founder & CSO 0 Teams Leadership Team 3
Other news to note for Sept. 25, 2023 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib m
MitoChem Therapeutics - HQ | The Org Platform Enrich Pricing Log in Sign up MitoChem Therapeutics Offices HQ Unverified HQ 0 people · 0 jobs MitoChem Therapeutics' headquarters in Charleston, SC, United States Office location People ( 0 ) No people in this office Jobs ( 0 ) No jobs in this office Other offices View all offices No other offices Company About Contact Blog Business Solutions Trust Pricing Directory Companies People Features Employer Branding Professional Networking Job Discovery Social © 2026 Orgio, Inc. Terms Privacy Do not sell my info
BioCentury - April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem This Edition ARTICLE | Regulation April 14 Quick Takes: GSK stops two trials of ICOS agonist; plus Trodelvy, Amylyx, Junshi, Jazz, MitoChem By BioCentury Staff April 15, 2021 1:19 AM UTC GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is discontinuing treatment with ICOS agonist feladilimab (GSK3359609) in two Phase II trials for metastatic head and neck squamous cell carcinoma following a recommendation by the independent data monitoring committee to stop the INDUCE-3 trial.
Preston joins NBSC board, Infinity Marketing adds 3 Skip to main content Home News Sports Life Downtown Business TALK Greenville Upstate Parent Opinion Obituaries Archives Media Storytellers eNewspaper Crosswords Comics Newsletters Upstate Parent For Subscribers Contributor Content Shopping Preston joins NBSC board, Infinity Marketing adds 3 Amanda Coyne | The Greenville News People on the move Tommy Preston, Jr., of Columbia, has been named to the South Carolina Local Board of Directors for NBSC . Preston is director of national strategy and engagement at Boeing South Carolina. He … dness,” according to an MUSC release. Beeson is the third person to receive the award, first given in 2013. Beeson has founded two Charleston-based startups focused on medical science. He developed the eye drops with his company Mitochem Therapeutics. Lloyd Kapp has been named medical director of BlueChoice HealthPlan of South Carolina. He also serves as medical director for BlueChoice and BlueCross BlueShield of South Carolina’s federally-facilitated exchange products. Kapp
Ichor Life Sciences Invests $1.5 Million in Mitochem Therapeutics for Ocular Aging Disease Research - Ichor Life Sciences Skip to content Services Protein Services Protein Expression & Purification Services Adeno-Associated Virus (AAV) Structural Biology Services X-Ray Crystallography Services Biophysical Assays Surface Plasmon Resonance Services Biacore Assay Services Circular Dichroism (CD) Assay Services nanoDSF Assay Services Bio-layer Interferometry Services Isothermal Titration Calorimetry Plate-Based Assay Services View All Protein Services Pharmacology Services Drug Discovery Serv
Podcasts - SCRA: South Carolina Research Authority Search for: SCRA Membership Menu Get to know SCRA Who We Are Mission Our Boards Board of Trustees Meeting Schedules S&T Meeting Schedule Document Center Our Team Working at SCRA Our Strategic Initiatives What We Do Center for Cybersecurity Center for Research Security Innovation Hubs Our Sustainability Our Impact Get Support SCRA Membership Grant Funding Tech Catalyst Fund Connect to Resources SCRA Member Benefits SCRA’s Startup Resources SCRA Webinars Podcasts Tech Startup Lifecycle Series Thought Leadership Series Solve Industry Needs G … Series Thought Leadership Series Solve Industry Needs Get Research Funding SACT Grant Establish South Carolina Location Lease Space Give Support Industry Partnership Fund IPF Newsletter SCRA’s Startup Resources Stay Connected News Media Kit Newsletter Social Freedom of Information Act SC Launch Who We Are Criteria and Eligibility Our Portfolio SCRA Membership SCRA Membership SCRA CEO Podcast The SCRA team is fortunate to work with some of the brightest minds in the startup wo … e an SCRA Member Company in October of 2022 and received a $50,000 Acceleration Grant. The company became an SC Launch Inc. Portfolio Company with SC Launch Inc.’s $200,000 investment in October of 2023. WAVS Custom is a Greenville-based startup that manufactures custom-fit ear audio products. It developed a 3D scanning and manufacturing platform that makes custom-fitted in-ear monitors (IEMs) that provide a higher degree of noise isolation for better sound. Visit company web … k.ai) became an SCRA Member Company in 2019 and received a $50,000 Acceleration Grant from SCRA in 2020. Later that year, they became an SC Launch, Inc. Portfolio Company by receiving their first $200,000 investment. In November of 2021, Hank received another $200,000 investment to help the artificial intelligence company continue its strong growth track of helping health care providers streamline their medical billing processes. Recognizing the need to simplify and improve e … ecame an SCRA Member Company in 2021 and received a $25,000 Project Development Fund Grant. They also became an SC Launch Inc. Portfolio Company with a $250,000 investment in May of 2023. As a solution to the problems businesses have managing multiple secure networks and maintaining privacy and security, Ruffian Software created an application, T
South Carolina Research Authority Newsroom: October 21, 2022 Here’s what’s happening in South Carolina - Don’t miss out! 🗓️ Click to View in Browser | October 21 , 2022 NEWS Listen to the SC Launch CEO Podcast featuring MitoChem Listen as Michael Voevodsky, president and CEO of MitoChem Therapeutics, discusses the history, challenges, and future of MitoChem. Founded at the Medical University of South Carolina, MitoChem Therapeutics was started by two scientists who saw an opportunity to focus on developing treatments to address the effects of cellular and metabolic dysfunction in neurod … s became an SCRA Member Company in 2019 and received a $25,000 Academic Startup Grant. The company became an SC Launch Inc. Portfolio Company with a $200,000 investment in August of 2022. Listen to the podcast. Unique Partnership Seeks to Advance Precision Medicine Options for Deadly GBM Brain Tumors Neurosurgical medical device innovator NICO Corporation and Kiyatec Inc., an SC Launch Inc. Portfolio Company and leader in functional precision oncology, announced a partnership
Our Eye on the Cure Podcast provides science news and insights from the world of vision. In this week's episode, host Ben Shaberman chats with Michael Voevodsky, MBA, CEO at MITOCHEM THERAPEUTICS… | Michele DiVincenzo LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choi
Lowcountry company MitoChem Therapeutics developing vision loss treatments - SCbio Skip to content Download the 2026 Economic Impact Report About About SCbio Team SCbio Board of Directors SCbio Office Locations Events Calendar Events at a Glance Life + Science Annual Conference BIO International Convention 2026 Drive Demo Day 2026 Sponsorships Membership Membership Benefits Member Login Complimentary Meeting Space Meet Our Members Students Programs Drive Accelerator Available Lab Space Workforce Development Economic Development Advocacy Entrepreneurship News Industry News Share Your Company Ne … ecame an SC Launch member company in 2019, receiving a $25,000 academic startup grant. Three years later, they became an SC Launch portfolio company with a $200,000 investment to assist in advancing adn commercializing their treatments to address vision loss. Dr. Beeson, a medicinal chemist and Professor of Drug Discovery and Biomedical Sciences, and Dr. Rohrer, a neuroscientist and Professor of Ophthalmology, both at Medical University of South Carolina, combined their exper
Team — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Team & Advi
2023 Annual SCRA Summit - SCRA: South Carolina Research Authority Search for: SCRA Membership Menu Get to know SCRA Who We Are Mission Our Boards Board of Trustees Meeting Schedules S&T Meeting Schedule Document Center Our Team Working at SCRA Our Strategic Initiatives What We Do Center for Cybersecurity Center for Research Security Innovation Hubs Our Sustainability Our Impact Get Support SCRA Membership Grant Funding Tech Catalyst Fund Connect to Resources SCRA Member Benefits SCRA’s Startup Resources SCRA Webinars Podcasts Tech Startup Lifecycle Series Thought Leadership Series Solve I … Series Thought Leadership Series Solve Industry Needs Get Research Funding SACT Grant Establish South Carolina Location Lease Space Give Support Industry Partnership Fund IPF Newsletter SCRA’s Startup Resources Stay Connected News Media Kit Newsletter Social Freedom of Information Act SC Launch Who We Are Criteria and Eligibility Our Portfolio SCRA Membership SCRA Membership 2023 Annual SCRA Summit Hundreds gathered at South Carolina Research Authority’s annual summit in Colu … ia-based TerraStride , was awarded Founder of the Year. GoodUnited developed an application that helps nonprofits raise money with their innovative two-way messaging platform that integrates with social media. TerraStride offers two products, TerraStride PRO, which allows users to tour a piece of land virtually, and HuntStand, the most popular hunting app in the country. TerraStride was recently acquired by industry giant GSM Outdoors. Themed Founders First , the summit is a
FFB award 2023Sep — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Mi … ontact Us MitoChem Therapeutics Receives $900,000 Foundation Fighting Blindness Award to Study Target and Mechanism of Action in Retinal Degenerative Diseases Charleston, S.C., September 21, 2023 – MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced today a $900,000 award from the Foundation Fighting Blindness. This funding will allow MitoChem to advance its understanding of the mechanism
Team 1 — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Bärbel (Barb) … toral training at UCSF. Professor Rohrer received the MUSC Inventor of the Year award in 2013, was elected to the rank of National Academy of Inventors fellow by a 2014 selection committee, obtained the Ernst H. Bárány Prize in Ocular Pharmacology from the International Society for Eye Research in 2018, and was chosen as one of the 10 members of The Ophthalmologist’s Power List 2019 in the Inventor Category. (photo curtesy: Ryan Jones) © Copyright 2025 MitoChem Therapeut
News — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us News MitoChem T … t Us News MitoChem Therapeutics Receives $900,000 Foundation Fighting Blindness Award to Study Target and Mechanism of Action in Retinal Degeneration Diseases September 21, 2023 SC Launch Inc. Announces Investment in MitoChem Therapeutics September 06, 2022 Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics For Ocular Aging Disease Research August 15, 2022 Press Release: MitoChem Therapeutics to Present at Mitochondria-Targeted Drug Development Summit February
MitoChem Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & … s became an SCRA Member Company in 2019 and received a $25,000 Academic Startup Grant. It became an SC Launch […] Sep 6, 2022 News: press release - 2022Aug15 - ICHOR Life Sciences Invests $1.5 Million — MitoChem Therapeutics, Inc Learn more by requesting a demo MitoChem Therapeutics Frequently Asked Questions (FAQ) When was MitoChem Therapeutics founded? MitoChem Therapeutics was founded in 2011. Where is MitoChem Therapeutics's headquarters? MitoChem Therapeutics's … Research Authority, SCRA’s Startup Resources, SCRA's Industry Partnership Fund and 3 more. Who are MitoChem Therapeutics's competitors? Competitors of MitoChem Therapeutics include Stealth BioTherapeutics. What products does MitoChem Therapeutics offer? MitoChem Therapeutics's products include MC16 (lead compound) and 1 more. Who are MitoChem Therapeutics's customers? Customers of MitoChem Therapeutics include NIH. Loading... Compare MitoChem Therapeutics
Ichor Life Sciences Invests $1.5 Million in MitoChem Therapeutics for Ocular Aging Disease Research | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Team 1 — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Michael Voevo
Photos — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Pipeline &
MitoChem Therapeutics to Present at Mitochondria-Targeted Drug Development Summit - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest MitoChem Therapeutics to Present at Mitochondria-Targeted Drug Development Summit February 23, 2022 | 2 min read Twitter LinkedIn Facebook Email Print MitoChem Therapeutics, Inc., a privately held company developing therapies for diseases involving mitochondrial dysfunction, announced that Bärbel Rohrer Ph.D. … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Restoring Cellular Metabolis
Partnering — MitoChem Therapeutics, Inc. 0 Skip to Content Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Science Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Open Menu Close Menu Home Folder: Science Back Science Cellular Energy & Neurodegeneration Molecular Target Mechanism of Action Pipeline & Indications Team Partnering News Contact Us Partnerin
MC-16 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 24 Apr 2026 MC-16 Last update 24 Apr 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms MC 16, MC-16 Target - Action - Mechanism - Therapeutic Areas Nervous System Diseases Congenital Disorders Endocrinology and Metabolic Disease + [2] Active Indication Amyotrophic Lateral Sclerosis Dystrophy, Macular Glaucoma + [1] Inactive Indication - Originato … pment incentives, including tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years upon FDA approval. About MitoChem Therapeutic MitoChem Therapeutics is a privately held company developing therapies for diseases involving mitochondrial dysfunction. The company was co-founded by the late Craig Beeson, PhD, and Bärbel Rohrer, PhD, to develop a new approach to treating neurodegeneration and aging diseases by focusing on prot